Human pathogens and the host cell sumoylation system

Journal of Virology

Volumn 86, Issue 2, 2012, Pages 642-654

  Wimmer, Peter ^a,b   Schreiner, Sabrina ^a   Dobner, Thomas ^a  

^a LEIBNIZ INSTITUTE FOR EXPERIMENTAL VIROLOGY   (Germany)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CELO GAM 1 PROTEIN; IE1 PROTEIN; IE2 PROTEIN; IMMEDIATE EARLY PROTEIN BZLF1; INFECTED CELL PROTEIN 0; LANA2 PROTEIN; ORF61 PROTEIN; PROTEIN UBC9; REGULATOR PROTEIN; RTA PROTEIN; SUMO 1 PROTEIN; SUMO 2 PROTEIN; SUMO 3 PROTEIN; TAX PROTEIN; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ADENOVIRUS; ARTICLE; BUNYAVIRUS; CELL COMPONENT; CELL TRANSFORMATION; CELLULAR DISTRIBUTION; CORONAVIRUS; EPSTEIN BARR VIRUS; FILOVIRIDAE; FLAVIVIRUS; HERPES SIMPLEX VIRUS 1; HERPES VIRUS; HOST PATHOGEN INTERACTION; HUMAN CYTOMEGALOVIRUS; HUMAN HERPESVIRUS 8; LISTERIA MONOCYTOGENES; NONHUMAN; NUCLEAR DOMAIN 10; ORTHOMYXOVIRUS; PAPILLOMA VIRUS; PARAMYXOVIRUS; PICORNAVIRUS; POXVIRUS; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA PROTEIN NUCLEAR BODY; PROTEIN LOCALIZATION; PROTEIN PROCESSING; PROTEIN STABILITY; RETROVIRUS; SUMOYLATION; TRANSCRIPTION REGULATION; VARICELLA ZOSTER VIRUS; VIRION; VIRUS CELL INTERACTION; VIRUS GENOME; VIRUS REPLICATION; YERSINIA;

ANIMALS; BACTERIAL INFECTIONS; BACTERIAL PHYSIOLOGICAL PHENOMENA; HOST-PATHOGEN INTERACTIONS; HUMANS; PROTEINS; SUMOYLATION; VIRUS DISEASES; VIRUS PHYSIOLOGICAL PHENOMENA;

EID: 84856862707     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.06227-11     Document Type: Article

References (203)

1. Adamson AL. 2005. Effects of SUMO-1 upon Epstein-Barr virus BZLF1 function and BMRF1 expression. Biochem. Biophys. Res. Commun. 336: 22-28.
2. Adamson AL, Kenney S. 2001. Epstein-Barr virus immediate-early protein BZLF1 is SUMO-1 modified and disrupts promyelocytic leukemia bodies. J. Virol. 75:2388-2399.
3. Ahn JH, Hayward GS. 1997. The major immediate-early proteins IE1 and IE2 of human cytomegalovirus colocalize with and disrupt PMLassociated nuclear bodies at very early times in infected permissive cells. J. Virol. 71:4599-4613.
4. Ahn JH, Xu Y, Jang WJ, Matunis MJ, Hayward GS. 2001. Evaluation of interactions of human cytomegalovirus immediate-early IE2 regulatory protein with small ubiquitin-like modifiers and their conjugation enzyme Ubc9. J. Virol. 75:3859-3872.
5. Alkuraya FS, et al. 2006. SUMO1 haploinsufficiency leads to cleft lip and palate. Science 313:1751.
6. Aribi M. 2008. Candidate genes implicated in type 1 diabetes susceptibility. Curr. Diabetes Rev. 4:110-121.
7. Babich A, Feldman LT, Nevins JR, Darnell JE, Weinberger C. 1983. Effect of adenovirus on metabolism of specific host mRNAs: transport control and specific translation discrimination. Mol. Cell. Biol. 3:1212-1221.
8. Bailey D, O'Hare P. 2002. Herpes simplex virus 1 ICP0 co-localizes with a SUMO-specific protease. J. Gen. Virol. 83:2951-2964.
9. Barrasa MI, Harel N, Yu Y, Alwine JC. 2003. Strain variations in single amino acids of the 86-kilodalton human cytomegalovirus major immediate-early protein (IE2) affect its functional and biochemical properties: implications of dynamic protein conformation. J. Virol. 77: 4760-4772.
10. Bawa-Khalfe T, Cheng J, Lin SH, Ittmann MM, Yeh ET. 2010. SENP1 induces prostatic intraepithelial neoplasia through multiple mechanisms. J. Biol. Chem. 285:25859-25866.
11. Bayer P, et al. 1998. Structure determination of the small ubiquitinrelated modifier SUMO-1. J. Mol. Biol. 280:275-286.
12. Berndt A, Hofmann-Winkler H, Tavalai N, Hahn G, Stamminger T. 2009. Importance of covalent and noncovalent SUMO interactions with the major human cytomegalovirus transactivator IE2p86 for viral infection. J. Virol. 83:12881-12894.
13. Boddy MN, Howe K, Etkin LD, Solomon E, Freemont PS. 1996. PIC 1, a novel ubiquitin-like protein which interacts with the PML component of a multiprotein complex that is disrupted in acute promyelocytic leukaemia. Oncogene 13:971-982.
14. Boggio R, Chiocca S. 2005. Gam1 and the SUMO pathway. Cell Cycle 4:533-535.
15. Boggio R, Chiocca S. 2006. Viruses and sumoylation: recent highlights. Curr. Opin. Microbiol. 9:430-436.
16. Boggio R, Colombo R, Hay RT, Draetta GF, Chiocca S. 2004. A mechanism for inhibiting the SUMO pathway. Mol. Cell 16:549-561.
17. Boggio R, Passafaro A, Chiocca S. 2007. Targeting SUMO E1 to ubiquitin ligases: a viral strategy to counteract sumoylation. J. Biol. Chem. 282:15376-15382.
18. Bohren KM, Nadkarni V, Song JH, Gabbay KH, Owerbach D. 2004. A M55V polymorphism in a novel SUMO gene (SUMO-4) differentially activates heat shock transcription factors and is associated with susceptibility to type I diabetes mellitus. J. Biol. Chem. 279:27233-27238.
19. Boutell C, et al. 2011. A viral ubiquitin ligase has substrate preferential SUMO targeted ubiquitin ligase activity that counteracts intrinsic antiviral defence. PLoS Pathog. 7:e1002245.
20. Boxus M, Willems L. 2009. Mechanisms of HTLV-1 persistence and transformation. Br. J. Cancer 101:1497-1501.
21. Brass AL, et al. 2008. Identification of host proteins required for HIV infection through a functional genomic screen. Science 319:921-926.
22. Burkham J, Coen DM, Hwang CB, Weller SK. 2001. Interactions of herpes simplex virus type 1 with ND10 and recruitment of PML to replication compartments. J. Virol. 75:2353-2367.
23. Burkham J, Coen DM, Weller SK. 1998. ND10 protein PML is recruited to herpes simplex virus type 1 prereplicative sites and replication compartments in the presence of viral DNA polymerase. J. Virol. 72: 10100-10107.
24. Carvalho T, et al. 1995. Targeting of adenovirus E1A and E4-ORF3 proteins to nuclear matrix-associated PML bodies. J. Cell Biol. 131: 45-56.
25. Chang LK, et al. 2004. Post-translational modification of Rta of Epstein-Barr virus by SUMO-1. J. Biol. Chem. 279:38803-38812.
26. Chang PC, et al. 2010. Kaposi's sarcoma-associated herpesvirus (KSHV) encodes a SUMO E3 ligase that is SIM-dependent and SUMO-2/3-specific. J. Biol. Chem. 285:5266-5273.
27. Chang TH, et al. 2009. Ebola Zaire virus blocks type I interferon production by exploiting the host SUMO modification machinery. PLoS Pathog. 5:e1000493.
28. Chang YL, et al. 2007. Regulation of nuclear receptor and coactivator functions by the carboxyl terminus of ubiquitin-conjugating enzyme 9. Int. J. Biochem. Cell Biol. 39:1035-1046.
29. Chelbi-Alix MK, de Thé H. 1999. Herpes virus induced proteasomedependent degradation of the nuclear bodies-associated PML and Sp100 proteins. Oncogene 18:935-941.
30. Chen SC, et al. 2011. Sumoylation-promoted enterovirus 71 3C degradation correlates with a reduction in viral replication and cell apoptosis. J. Biol. Chem. 286:31373-31384.
31. Chiocca S. 2007. Viral control of the SUMO pathway: Gam1, a model system. Biochem. Soc. Trans. 35:1419-1421.
32. Chiocca S, Baker A, Cotten M. 1997. Identification of a novel antiapoptotic protein, GAM-1, encoded by the CELO adenovirus. J. Virol. 71:3168-3177.
33. Chiocca S, et al. 2002. Histone deacetylase 1 inactivation by an adenovirus early gene product. Current Biol. 12:594-598.
34. Chiu MW, Shih HM, Yang TH, Yang YL. 2007. The type 2 dengue virus envelope protein interacts with small ubiquitin-like modifier-1 (SUMO-1) conjugating enzyme 9 (Ubc9). J. Biomed. Sci. 14:429-444.
35. Citro S, Chiocca S. 2010. Listeria monocytogenes: a bacterial pathogen to hit on the SUMO pathway. Cell Res. 20:738-740.
36. Colombo R, Boggio R, Seiser C, Draetta GF, Chiocca S. 2002. The adenovirus protein Gam1 interferes with sumoylation of histone deacetylase 1. EMBO Rep. 3:1062-1068.
37. Cornelis GR. 2002. The Yersinia Ysc-Yop virulence apparatus. Int. J. Med. Microbiol. 291:455-462.
38. Cornelis GR, Denecker G. 2001. Yersinia lead SUMO attack. Nature Med. 7:21-23.
39. Cuchet-Lourenço D, et al. 2011. SUMO pathway dependent recruitment of cellular repressors to herpes simplex virus type 1 genomes. PLoS Pathog. 7:e1002123.
40. Deng H, et al. Over-accumulation of nuclear IGF-1 receptor in tumor cells requires elevated expression of the receptor and the SUMOconjugating enzyme Ubc9. 2011. Biochem. Biophys. Res. Commun. 404: 667-671.
41. Deyrieux AF, Rosas-Acosta G, Ozbun MA, Wilson VG. 2007. Sumoylation dynamics during keratinocyte differentiation. J. Cell Sci. 120: 125-136.
42. Doucas V, et al. 1996. Adenovirus replication is coupled with the dynamic properties of the PML nuclear structure. Genes Dev. 10:196-207.
43. Dunnebier T, et al. 2010. Polymorphisms in the UBC9 and PIAS3 genes of the SUMO-conjugating system and breast cancer risk. Breast Cancer Res. Treat 121:185-194.
44. Endter C, Hartl B, Spruss T, Hauber J, Dobner T. 2005. Blockage of CRM1-dependent nuclear export of the adenovirus type 5 early region 1B 55-kDa protein augments oncogenic transformation of primary rat cells. Oncogene 24:55-64.
45. Endter C, Kzhyshkowska J, Stauber R, Dobner T. 2001. SUMO-1 modification required for transformation by adenovirus type 5 early region 1B 55-kDa oncoprotein. Proc. Natl. Acad. Sci. U. S. A. 98: 11312-11317.
46. Everett RD. 2001. DNA viruses and viral proteins that interact with PML nuclear bodies. Oncogene 20:7266-7273.
47. Everett RD, Chelbi-Alix MK. 2007. PML and PML nuclear bodies: implications in antiviral defence. Biochimie 89:819-830.
48. Everett RD, et al. 1998. The disruption of ND10 during herpes simplex virus infection correlates with the Vmw110- and proteasome-dependent loss of several PML isoforms. J. Virol. 72:6581-6591.
49. Everett RD, et al. 1997. A novel ubiquitin-specific protease is dynamically associated with the PML nuclear domain and binds to a herpesvirus regulatory protein. EMBO J. 16:1519-1530.
50. Everett RD, Murray J. 2005. ND10 components relocate to sites associated with herpes simplex virus type 1 nucleoprotein complexes during virus infection. J. Virol. 79:5078-5089.
51. Everett RD, Murray J, Orr A, Preston CM. 2007. Herpes simplex virus type 1 genomes are associated with ND10 nuclear substructures in quiescently infected human fibroblasts. J. Virol. 81:10991-11004.
52. Everett RD, Parada C, Gripon P, Sirma H, Orr A. 2008. Replication of ICP0-null mutant herpes simplex virus type 1 is restricted by both PML and Sp100. J. Virol. 82:2661-2672.
53. Everett RD, et al. 2006. PML contributes to a cellular mechanism of repression of herpes simplex virus type 1 infection that is inactivated by ICP0. J. Virol. 80:7995-8005.
54. Everett RD, Sourvinos G, Leiper C, Clements JB, Orr A. 2004. Formation of nuclear foci of the herpes simplex virus type 1 regulatory protein ICP4 at early times of infection: localization, dynamics, recruitment of ICP27, and evidence for the de novo induction of ND10-like complexes. J. Virol. 78:1903-1917.
55. Fan Z, et al. 2006. SARS-CoV nucleocapsid protein binds to hUbc9, a ubiquitin conjugating enzyme of the sumoylation system. J. Med. Virol. 78:1365-1373.
56. Fradet-Turcotte A, Brault K, Titolo S, Howley PM, Archambault J. 2009. Characterization of papillomavirus E1 helicase mutants defective for interaction with the SUMO-conjugating enzyme Ubc9. Virology 395: 190-201.
57. Freed EO. 2002. Viral late domains. J. Virol. 76:4679-4687.
58. Frisch SM, Mymryk JS. 2002. Adenovirus-5 E1A: paradox and paradigm. Nat. Rev. Mol. Cell Biol. 3:441-452.
59. Geiss-Friedlander R, Melchior F. 2007. Concepts in sumoylation: a decade on. Nat. Rev. Mol. Cell Biol. 8:947-956.
60. Geoffroy MC, Jaffray EG, Walker KJ, Hay RT. 2010. Arsenic-induced SUMO-dependent recruitment of RNF4 into PML nuclear bodies. Mol. Biol. Cell 21:4227-4239.
61. Gomes R, Guerra-Sa R, Arruda E. 2010. Coxsackievirus B5 induced apoptosis of HeLa cells: effects on p53 and SUMO. Virology 396: 256-263.
62. González-Santamaría J, et al. 2011. Regulation of vaccinia virus E3 protein by small ubiquitin-like modifier proteins. J. Virol. 85: 12890-12900.
63. Gravel A, Dion V, Cloutier N, Gosselin J, Flamand L. 2004. Characterization of human herpesvirus 6 variant B immediate-early 1 protein modifications by small ubiquitin-related modifiers. J. Gen. Virol. 85: 1319-1328.
64. Gravel A, Gosselin J, Flamand L. 2002. Human herpesvirus 6 immediate-early 1 protein is a sumoylated nuclear phosphoprotein colocalizing with promyelocytic leukemia protein-associated nuclear bodies. J. Biol. Chem. 277:19679-19687.
65. Gurer C, Berthoux L, Luban J. 2005. Covalent modification of human immunodeficiency virus type 1 p6 by SUMO-1. J. Virol. 79:910-917.
66. Hagemeier C, Walker SM, Sissons PJ, Sinclair JH. 1992. The 72K IE1 and 80K IE2 proteins of human cytomegalovirus independently transactivate the c-fos, c-myc and hsp70 promoters via basal promoter elements. J. Gen. Virol. 73:2385-2393.
67. Hagemeier SR, et al. 2010. Sumoylation of the Epstein-Barr virus BZLF1 protein inhibits its transcriptional activity and is regulated by the virusencoded protein kinase. J. Virol. 84:4383-4394.
68. Han Y, et al. 2010. SENP3-mediated de-conjugation of SUMO2/3 from promyelocytic leukemia is correlated with accelerated cell proliferation under mild oxidative stress. J. Biol. Chem. 285:12906-12915.
69. Hannoun Z, Greenhough S, Jaffray E, Hay RT, Hay DC. 2010. Posttranslational modification by SUMO. Toxicology 278:288-293.
70. Hateboer G, et al. 1996. mUBC9, a novel adenovirus E1A-interacting protein that complements a yeast cell cycle defect. J. Biol. Chem. 271: 25906-25911.
71. Hay RT. 2005. SUMO: a history of modification. Mol. Cell 18:1-12.
72. Hayashi T, et al. 2002. Ubc9 is essential for viability of higher eukaryotic cells. Exp. Cell Res. 280:212-221.
73. Hermiston TW, Malone CL, Stinski MF. 1990. Human cytomegalovirus immediate-early two protein region involved in negative regulation of the major immediate-early promoter. J. Virol. 64:3532-3536.
74. Hietakangas V, et al. 2006. PDSM, a motif for phosphorylationdependent SUMO modification. Proc. Natl. Acad. Sci. U. S. A. 103: 45-50.
75. Hochstrasser M. 2009. Origin and function of ubiquitin-like proteins. Nature 458:422-429.
76. Hofmann H, Floss S, Stamminger T. 2000. Covalent modification of the transactivator protein IE2-p86 of human cytomegalovirus by conjugation to the ubiquitin-homologous proteins SUMO-1 and hSMT3b. J. Virol. 74:2510-2524.
77. Huh YH, et al. 2008. Binding STAT2 by the acidic domain of human cytomegalovirus IE1 promotes viral growth and is negatively regulated by SUMO. J. Virol. 82:10444-10454.
78. Izumiya Y, et al. 2005. Kaposi's sarcoma-associated herpesvirus K-bZIP represses gene transcription via SUMO modification. J. Virol. 79: 9912-9925.
79. Jaber T, et al. 2009. Human Ubc9 contributes to production of fully infectious human immunodeficiency virus type 1 virions. J. Virol. 83: 10448-10459.
80. Johnson ES. 2004. Protein modification by SUMO. Annu. Rev. Biochem. 73:355-382.
81. Johnson ES, Gupta AA. 2001. An E3-like factor that promotes SUMO conjugation to the yeast septins. Cell 106:735-744.
82. Kaikkonen S, et al. 2009. SUMO-specific protease 1 (SENP1) reverses the hormone-augmented SUMOylation of androgen receptor and modulates gene responses in prostate cancer cells. Mol. Endocrinol. 23: 292-307.
83. Kang H, et al. 2006. Inhibition of SUMO-independent PML oligomerization by the human cytomegalovirus IE1 protein. J. Gen. Virol. 87: 2181-2190.
84. Kaukinen P, Vaheri A, Plyusnin A. 2003. Non-covalent interaction between nucleocapsid protein of Tula hantavirus and small ubiquitinrelated modifier-1, SUMO-1. Virus Res. 92:37-45.
85. Kaul S, Blackford JA Jr, Cho S, Simons SS Jr. 2002. Ubc9 is a novel modulator of the induction properties of glucocorticoid receptors. J. Biol. Chem. 277:12541-12549.
86. Kehn K, et al. 2004. Mechanisms of HTLV-1 transformation. Front. Biosci. 9:2347-2372.
87. Kelly C, Van Driel R, Wilkinson GW. 1995. Disruption of PMLassociated nuclear bodies during human cytomegalovirus infection. J. Gen. Virol. 76:2887-2893.
88. Kerscher O. 2007. SUMO junction-what's your function? New insights through SUMO-interacting motifs. EMBO Rep. 8:550-555.
89. Kerscher O, Felberbaum R, Hochstrasser M. 2006. Modification of proteins by ubiquitin and ubiquitin-like proteins. Annu. Rev. Cell Dev. Biol. 22:159-180.
90. Kfoury Y, et al. 2011. Tax ubiquitylation and SUMOylation control the dynamic shuttling of Tax and NEMO between Ubc9 nuclear bodies and the centrosome. Blood 117:190-199.
91. Kim ET, Kim YE, Huh YH, Ahn JH. 2010. Role of noncovalent SUMO binding by the human cytomegalovirus IE2 transactivator in lytic growth. J. Virol. 84:8111-8123.
92. Kindsmüller K, et al. 2007. Intranuclear targeting and nuclear export of the adenovirus E1B-55K protein are regulated by SUMO1 conjugation. Proc. Natl. Acad. Sci. U. S. A. 104:6684-6689.
93. Kobayashi S, et al. 2004. Ubc9 interacts with chicken ovalbumin upstream promoter-transcription factor I and represses receptordependent transcription. J. Mol. Endocrinol. 32:69-86.
94. König R, et al. 2010. Human host factors required for influenza virus replication. Nature 463:813-817.
95. König R, et al. 2008. Global analysis of host-pathogen interactions that regulate early-stage HIV-1 replication. Cell 135:49-60.
96. Kubota T, et al. 2008. Virus infection triggers SUMOylation of IRF3 and IRF7, leading to the negative regulation of type I interferon gene expression. J. Biol. Chem. 283:25660-25670.
97. Kurtzman AL, Schechter N. 2001. Ubc9 interacts with a nuclear localization signal and mediates nuclear localization of the paired-like homeobox protein Vsx-1 independent of SUMO-1 modification. Proc. Natl. Acad. Sci. U. S. A. 98:5602-5607.
98. Kyratsous CA, Silverstein SJ. 2009. Components of nuclear domain 10 bodies regulate varicella-zoster virus replication. J. Virol. 83:4262-4274.
99. Lallemand-Breitenbach V, et al. 2008. Arsenic degrades PML or PMLRARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway. Nat. Cell Biol. 10:547-555.
100. Lamsoul I, et al. 2005. Exclusive ubiquitination and sumoylation on overlapping lysine residues mediate NF-kappaB activation by the human T-cell leukemia virus tax oncoprotein. Mol. Cell. Biol. 25:10391-10406.
101. Lang M, et al. 2010. Three-dimensional organization of promyelocytic leukemia nuclear bodies. J. Cell Sci. 123:392-400.
102. Lee BH, et al. 2003. Association of the nucleocapsid protein of the Seoul and Hantaan hantaviruses with small ubiquitin-like modifier-1-related molecules. Virus Res. 98:83-91.
103. Lee HR, Ahn JH. 2004. Sumoylation of the major immediate-early IE2 protein of human cytomegalovirus Towne strain is not required for virus growth in cultured human fibroblasts. J. Gen. Virol. 85:2149-2154.
104. Lee HR, et al. 2004. Ability of the human cytomegalovirus IE1 protein to modulate sumoylation of PML correlates with its functional activities in transcriptional regulation and infectivity in cultured fibroblast cells. J. Virol. 78:6527-6542.
105. Lee JM, et al. 2003. PIAS1 enhances SUMO-1 modification and the transactivation activity of the major immediate-early IE2 protein of human cytomegalovirus. FEBS Lett. 555:322-328.
106. Lee P, Hruby DE. 1994. Proteolytic cleavage of vaccinia virus virion proteins: mutational analysis of the specificity determinants. J. Biol. Chem. 269:8616-8622.
107. Lethbridge KJ, Scott GE, Leppard KN. 2003. Nuclear matrix localization and SUMO-1 modification of adenovirus type 5 E1b 55K protein are controlled by E4 Orf6 protein. J. Gen. Virol. 84:259-268.
108. Li FQ, Xiao H, Tam JP, Liu DX. 2005. Sumoylation of the nucleocapsid protein of severe acute respiratory syndrome coronavirus. FEBS Lett. 579:2387-2396.
109. Li Q, Xiao H, Tam JP, Liu DX. 2006. Sumoylation of the nucleocapsid protein of severe acute respiratory syndrome coronavirus by interaction with Ubc9. Adv. Exp. Med. Biol. 581:121-126.
110. Li SJ, Hochstrasser M. 1999. A new protease required for cell-cycle progression in yeast. Nature 398:246-251.
111. Li XH, Gaynor RB. 2000. Mechanisms of NF-kappaB activation by the HTLV type 1 tax protein. AIDS Res. Hum. Retroviruses 16:1583-1590.
112. Liu ST, et al. 2006. Sumoylation of Rta of Epstein-Barr virus is preferentially enhanced by PIASxbeta. Virus Res. 119:163-170.
113. López-Otín C, Simon-Mateo C, Martinez L, Vinuela E. 1989. Gly-Gly-X, a novel consensus sequence for the proteolytic processing of viral and cellular proteins. J. Biol. Chem. 264:9107-9110.
114. Lukashchuk V, Everett RD. 2010. Regulation of ICP0-null mutant herpes simplex virus type 1 infection by ND10 components ATRX and hDaxx. J. Virol. 84:4026-4040.
115. Maeda A, et al. 2003. The intracellular association of the nucleocapsid protein (NP) of hantaan virus (HTNV) with small ubiquitin-like modifier-1 (SUMO-1) conjugating enzyme 9 (Ubc9). Virology 305: 288-297.
116. Mahajan R, Delphin C, Guan T, Gerace L, Melchior F. 1997. A small ubiquitin-related polypeptide involved in targeting RanGAP1 to nuclear pore complex protein RanBP2. Cell 88:97-107.
117. Malone CL, Vesole DH, Stinski MF. 1990. Transactivation of a human cytomegalovirus early promoter by gene products from the immediateearly gene IE2 and augmentation by IE1: mutational analysis of the viral proteins. J. Virol. 64:1498-1506.
118. Marcos-Villar L, et al. 2011. Covalent modification by SUMO is required for efficient disruption of PML oncogenic domains by Kaposi's sarcoma-associated herpesvirus latent protein LANA2. J. Gen. Virol. 92: 188-194.
119. Marcos-Villar L, et al. 2009. Kaposi's sarcoma-associated herpesvirus protein LANA2 disrupts PML oncogenic domains and inhibits PMLmediated transcriptional repression of the survivin gene. J. Virol. 83: 8849-8858.
120. Marusic MB, Mencin N, Licen M, Banks L, Grm HS. 2010. Modification of human papillomavirus minor capsid protein L2 by sumoylation. J. Virol. 84:11585-11589.
121. Matic I, et al. 2010. Site-specific identification of SUMO-2 targets in cells reveals an inverted SUMOylation motif and a hydrophobic cluster SUMOylation motif. Mol. Cell 39:641-652.
122. Matunis MJ, Coutavas E, Blobel G. 1996. A novel ubiquitin-like modification modulates the partitioning of the Ran-GTPase-activating protein RanGAP1 between the cytosol and the nuclear pore complex. J. Cell Biol. 135:1457-1470.
123. Maul GG, Everett RD. 1994. The nuclear location of PML, a cellular member of the C3HC4 zinc-binding domain protein family, is rearranged during herpes simplex virus infection by the C3HC4 viral protein ICP0. J. Gen. Virol. 75:1223-1233.
124. Maul GG, Guldner HH, Spivack JG. 1993. Modification of discrete nuclear domains induced by herpes simplex virus type 1 immediate early gene 1 product (ICP0). J. Gen. Virol. 74:2679-2690.
125. Meluh PB, Koshland D. 1995. Evidence that the MIF2 gene of Saccharomyces cerevisiae encodes a centromere protein with homology to the mammalian centromere protein CENP-C. Mol. Biol. Cell 6:793-807.
126. Mo YY, Moschos SJ. 2005. Targeting Ubc9 for cancer therapy. Expert Opin. Ther. Targets 9:1203-1216.
127. Moschos S. J, et al. 2010. Expression analysis of Ubc9, the single small ubiquitin-like modifier (SUMO) E2 conjugating enzyme, in normal and malignant tissues. Hum. Pathol. 41:1286-1298.
128. Mossessova E, Lima CD. 2000. Ulp1-SUMO crystal structure and genetic analysis reveal conserved interactions and a regulatory element essential for cell growth in yeast. Mol. Cell 5:865-876.
129. Mukhopadhyay D, Dasso M. 2007. Modification in reverse: the SUMO proteases. Trends Biochem. Sci. 32:286-295.
130. Muller S, Dejean A. 1999. Viral immediate-early proteins abrogate the modification by SUMO-1 of PML and Sp100 proteins, correlating with nuclear body disruption. J. Virol. 73:5137-5143.
131. Murata T, et al. 2010. Transcriptional repression by sumoylation of Epstein-Barr virus BZLF1 protein correlates with association of histone deacetylase. J. Biol. Chem. 285:23925-23935.
132. Nacerddine K, et al. 2005. The SUMO pathway is essential for nuclear integrity and chromosome segregation in mice. Dev. Cell 9:769-779.
133. Nevels M, Brune W, Shenk T. 2004. SUMOylation of the human cytomegalovirus 72-kilodalton IE1 protein facilitates expression of the 86-kilodalton IE2 protein and promotes viral replication. J. Virol. 78: 7803-7812.
134. Nowak M, Hammerschmidt M. 2006. Ubc9 regulates mitosis and cell survival during zebrafish development. Mol. Biol. Cell 17:5324-5336.
135. Okura T, et al. 1996. Protection against Fas/APO-1- and tumor necrosis factor-mediated cell death by a novel protein, sentrin. J. Immunol. 157: 4277-4281.
136. Orth K. 2002. Function of the Yersinia effector YopJ. Curr. Opin. Microbiol. 5:38-43.
137. Reference deleted
138. Orth K, et al. 2000. Disruption of signaling by Yersinia effector YopJ, a ubiquitin-like protein protease. Science 290:1594-1597.
139. Ott DE, Coren LV, Chertova EN, Gagliardi TD, Schubert U. 2000. Ubiquitination of HIV-1 and MuLV Gag. Virology 278:111-121.
140. Owerbach D, McKay EM, Yeh ET, Gabbay KH, Bohren KM. 2005. A proline-90 residue unique to SUMO-4 prevents maturation and sumoylation. Biochem. Biophys. Res. Commun. 337:517-520.
141. Pal S, Rosas JM, Rosas-Acosta G. 2010. Identification of the nonstructural influenza A viral protein NS1A as a bona fide target of the Small Ubiquitin-like MOdifier by the use of dicistronic expression constructs. J. Virol. Methods 163:498-504.
142. Pal S, Santos A, Rosas JM, Ortiz-Guzman J, Rosas-Acosta G. 2011. Influenza A virus interacts extensively with the cellular SUMOylation system during infection. Virus Res. 158:12-27.
143. Palacios S, et al. 2005. Quantitative SUMO-1 modification of a vaccinia virus protein is required for its specific localization and prevents its selfassociation. Mol. Biol. Cell 16:2822-2835.
144. Pan X, et al. 2006. Ubc9 interacts with SOX4 and represses its transcriptional activity. Biochem. Biophys. Res. Commun. 344:727-734.
145. Parkinson J, Everett RD. 2000. Alphaherpesvirus proteins related to herpes simplex virus type 1 ICP0 affect cellular structures and proteins. J. Virol. 74:10006-10017.
146. Peloponese JM Jr, Kinjo T, Jeang KT. 2007. Human T-cell leukemia virus type 1 Tax and cellular transformation. Int. J. Hematol. 86:101-106.
147. Pennella MA, Liu Y, Woo JL, Kim CA, Berk AJ. 2010. Adenovirus E1B 55-kilodalton protein is a p53-SUMO1 E3 ligase that represses p53 and stimulates its nuclear export through interactions with promyelocytic leukemia nuclear bodies. J. Virol. 84:12210-12225.
148. Petrie K, Zelent A. 2008. Marked for death. Nat. Cell Biol. 10:507-509.
149. Pizzorno MC, O'Hare P, Sha L, LaFemina RL, Hayward GS. 1988. trans-Activation and autoregulation of gene expression by the immediate-early region 2 gene products of human cytomegalovirus. J. Virol. 62:1167-1179.
150. Pornillos O, Alam SL, Davis DR, Sundquist WI. 2002. Structure of the Tsg101 UEV domain in complex with the PTAP motif of the HIV-1 p6 protein. Nat. Struct. Biol. 9:812-817.
151. Pornillos O, et al. 2002. Structure and functional interactions of the Tsg101 UEV domain. EMBO J. 21:2397-2406.
152. Pozzebon M, Segre CV, Chiocca S. 2009. Inhibition of the SUMO pathway by Gam1. Methods Mol. Biol. 497:285-301.
153. Prudden J, et al. 2007. SUMO-targeted ubiquitin ligases in genome stability. EMBO J. 26:4089-4101.
154. Puvion-Dutilleul F, et al. 1995. Adenovirus infection induces rearrangements in the intranuclear distribution of the nuclear body-associated PML protein. Exp. Cell Res. 218:9-16.
155. Rangasamy D, Wilson VG. 2000. Bovine papillomavirus E1 protein is sumoylated by the host cell Ubc9 protein. J. Biol. Chem. 275: 30487-30495.
156. Rangasamy D, Woytek K, Khan SA, Wilson VG. 2000. SUMO-1 modification of bovine papillomavirus E1 protein is required for intranuclear accumulation. J. Biol. Chem. 275:37999-38004.
157. Reichelt M, et al. 2011. Entrapment of viral capsids in nuclear PML cages is an intrinsic antiviral host defense against varicella-zoster virus. PLoS Pathog. 7:e1001266.
158. Ribet D, et al. 2010. Listeria monocytogenes impairs SUMOylation for efficient infection. Nature 464:1192-1195.
159. Rogan S, Heaphy S. 2000. The vaccinia virus E3L protein interacts with SUMO-1 and ribosomal protein L23a in a yeast two hybrid assay. Virus Genes 21:193-195.
160. Rosas-Acosta G, Langereis MA, Deyrieux A, Wilson VG. 2005. Proteins of the PIAS family enhance the sumoylation of the papillomavirus E1 protein. Virology 331:190-203.
161. Rosendorff A, et al. 2004. EBNA3C coactivation with EBNA2 requires a SUMO homology domain. J. Virol. 78:367-377.
162. Sadanari H, Yamada R, Ohnishi K, Matsubara K, Tanaka J. 2005. SUMO-1 modification of the major immediate-early (IE) 1 and 2 proteins of human cytomegalovirus is regulated by different mechanisms and modulates the intracellular localization of the IE1, but not IE2, protein. Arch. Virol. 150:1763-1782.
163. Saitoh H, Hinchey J. 2000. Functional heterogeneity of small ubiquitinrelated protein modifiers SUMO-1 versus SUMO-2/3. J. Biol. Chem. 275:6252-6258.
164. Saltzman A, et al. 1998. hUBC9 associates with MEKK1 and type I TNF-alpha receptor and stimulates NFkappaB activity. FEBS Lett. 425: 431-435.
165. Sapp M, Bienkowska-Haba M. 2009. Viral entry mechanisms: human papillomavirus and a long journey from extracellular matrix to the nucleus. FEBS J. 276:7206-7216.
166. Sarge KD, Park-Sarge OK. 2009. Sumoylation and human disease pathogenesis. Trends Biochem. Sci. 34:200-205.
167. Schreiner S, et al. 2011. Adenovirus type 5 early region 1B 55K oncoprotein dependent degradation of cellular factor Daxx is required for efficient transformation of primary rodent cells. J. Virol. 85:8752-8765.
168. Schreiner S, et al. 2010. Proteasome-dependent degradation of Daxx by the viral E1B-55K protein in human adenovirus-infected cells. J. Virol. 84:7029-7038.
169. Schwartz DC, Hochstrasser M. 2003. A superfamily of protein tags: ubiquitin, SUMO and related modifiers. Trends Biochem. Sci. 28: 321-328.
170. Shapira SD, et al. 2009. A physical and regulatory map of host-influenza interactions reveals pathways in H1N1 infection. Cell 139:1255-1267.
171. Shen TH, Lin HK, Scaglioni PP, Yung TM, Pandolfi PP. 2006. The mechanisms of PML-nuclear body formation. Mol. Cell 24:331-339.
172. Sia C. 2005. Is a new immune response mediator in the NF-kappaB pathway-SUMO-4-related to type 1 diabetes? Rev. Diabet. Stud. 2:58-60.
173. Song J, Durrin LK, Wilkinson TA, Krontiris TG, Chen Y. 2004. Identification of a SUMO-binding motif that recognizes SUMOmodified proteins. Proc. Natl. Acad. Sci. U. S. A. 101:14373-14378.
174. Spengler ML, Kurapatwinski K, Black AR, Azizkhan-Clifford J. 2002. SUMO-1 modification of human cytomegalovirus IE1/IE72. J. Virol. 76: 2990-2996.
175. Sun D, Xu P, He B. 2011. Sumoylation of the P protein at K254 plays an important role in growth of parainfluenza virus 5. J. Virol. 85: 10261-10268.
176. Sun H, Leverson JD, Hunter T. 2007. Conserved function of RNF4 family proteins in eukaryotes: targeting a ubiquitin ligase to SUMOylated proteins. EMBO J. 26:4102-4112.
177. Tatham MH, et al. 2008. RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation. Nat. Cell Biol. 10: 538-546.
178. Tavalai N, Stamminger T. 2008. New insights into the role of the subnuclear structure ND10 for viral infection. Biochim. Biophys. Acta 1783: 2207-2221.
179. Tomoiu A, Gravel A, Tanguay RM, Flamand L. 2006. Functional interaction between human herpesvirus 6 immediate-early 2 protein and ubiquitin-conjugating enzyme 9 in the absence of sumoylation. J. Virol. 80:10218-10228.
180. Ulrich HD. 2009. The SUMO system: an overview. Methods Mol. Biol. 497:3-16.
181. Uzunova K, et al. 2007. Ubiquitin-dependent proteolytic control of SUMO conjugates. J. Biol. Chem. 282:34167-34175.
182. Van Damme E, Laukens K, Dang TH, Van Ostade X. 2010. A manually curated network of the PML nuclear body interactome reveals an important role for PML-NBs in SUMOylation dynamics. Int. J. Biol. Sci. 6:51-67.
183. Van Damme E, Van Ostade X. 2011. Crosstalk between viruses and PML nuclear bodies: a network-based approach. Front. Biosci. 17: 2910-2920.
184. Verger A, Perdomo J, Crossley M. 2003. Modification with SUMO: a role in transcriptional regulation. EMBO Rep. 4:137-142.
185. VerPlank L, et al. 2001. Tsg101, a homologue of ubiquitin-conjugating (E2) enzymes, binds the L domain in HIV type 1 Pr55(Gag). Proc. Natl. Acad. Sci. U. S. A. 98:7724-7729.
186. Wang L, et al. 2011. Disruption of PML nuclear bodies is mediated by ORF61 SUMO-interacting motifs and required for varicella-zoster virus pathogenesis in skin. PLoS Pathog. 7:e1002157.
187. Weidtkamp-Peters S, et al. 2008. Dynamics of component exchange at PML nuclear bodies. J. Cell Sci. 121:2731-2743.
188. Weisshaar SR, et al. 2008. Arsenic trioxide stimulates SUMO-2/3 modification leading to RNF4-dependent proteolytic targeting of PML. FEBS Lett. 582:3174-3178.
189. Weldon RA Jr, Sarkar P, Brown SM, Weldon SK. 2003. Mason-Pfizer monkey virus Gag proteins interact with the human sumo conjugating enzyme, hUbc9. Virology 314:62-73.
190. Wilson VG, Rangasamy D. 2001. Viral interaction with the host cell sumoylation system. Virus Res. 81:17-27.
191. Wimmer P, et al. 2010. SUMO modification of E1B-55K oncoprotein regulates isoform-specific binding to the tumour suppressor protein PML. Oncogene 29:5511-5522.
192. Wu CY, Jeng KS, Lai MM. 2011. The SUMOylation of matrix protein M1 modulates the assembly and morphogenesis of influenza A virus. J. Virol. 85:6618-6628.
193. Wu YC, Bian XL, Heaton PR, Deyrieux AF, Wilson VG. 2009. Host cell sumoylation level influences papillomavirus E2 protein stability. Virology 387:176-183.
194. Wu YC, Deyrieux AF, Wilson VG. 2007. Papillomaviruses and the host SUMOylation system. Biochem. Soc. Trans. 35:1433-1435.
195. Wu YC, Roark AA, Bian XL, Wilson VG. 2008. Modification of papillomavirus E2 proteins by the small ubiquitin-like modifier family members (SUMOs). Virology 378:329-338.
196. Xie Y, et al. 2007. The yeast Hex3.Slx8 heterodimer is a ubiquitin ligase stimulated by substrate sumoylation. J. Biol. Chem. 282:34176-34184.
197. Xu K, et al. 2011. Modification of nonstructural protein 1 of influenza A virus by SUMO1. J. Virol. 85:1086-1098.
198. Yang SH, Galanis A, Witty J, Sharrocks AD. 2006. An extended consensus motif enhances the specificity of substrate modification by SUMO. EMBO J. 25:5083-5093.
199. Yasugi T, Vidal M, Sakai H, Howley PM, Benson JD. 1997. Two classes of human papillomavirus type 16 E1 mutants suggest pleiotropic conformational constraints affecting E1 multimerization, E2 interaction, and interaction with cellular proteins. J. Virol. 71:5942-5951.
200. Yousef AF, et al. 2010. Identification of a molecular recognition feature in the E1A oncoprotein that binds theSUMOconjugase UBC9 and likely interferes with polySUMOylation. Oncogene 29:4693-4704.
201. Yueh A, et al. 2006. Interaction of moloney murine leukemia virus capsid with Ubc9 and PIASy mediates SUMO-1 addition required early in infection. J. Virol. 80:342-352.
202. Zamborlini A, et al. 2011. Impairment of human immunodeficiency virus type-1 integrase SUMOylation correlates with an early replication defect. J. Biol. Chem. 286:21013-21022.
203. Zhu S, Sachdeva M, Wu F, Lu Z, Mo YY. 2010. Ubc9 promotes breast cell invasion and metastasis in a sumoylation-independent manner. Oncogene 29:1763-1772.